US Patent 5,773,020: Claim Scope, Expiration, Orange Book Position and Alprostadil Patent Landscape

US Patent 5,773,020 covers an intraurethral dosage form for erectile dysfunction. Its core combination is a urethra-sized shaft containing a rapidly dispersible composition with a vasoactive prostaglandin. The broadest claim does not require alprostadil, prazosin, polyethylene glycol, a specific dose, or a particular device material. The patent is directed to the dosage-form architecture and its urethral delivery function.

The patent’s enforceable life has ended. It does not create a current exclusionary barrier to generic or competing intraurethral alprostadil products, although its claim language remains relevant to historical freedom-to-operate reviews, patent-family analysis, and interpretation of later MUSE-related patents.

What does US Patent 5,773,020 protect?

US Patent 5,773,020 protects a dosage form having four required elements:

A shaft sized for insertion into the male urethra.
A composition retained within the shaft.
An effective amount of a vasoactive prostaglandin in the composition.
At least one dispersant.

Claim 1 is the principal independent claim. It is a combination claim, meaning that an accused product must satisfy every limitation. A product containing alprostadil but lacking a shaft, urethral insertion capability, or a dispersant would not fall within claim 1 as written.

The claim is broader than a claim limited to MUSE, alprostadil, polyethylene glycol, or a particular applicator. It covers a class of intraurethral dosage forms using prostaglandins and materials that dissolve, melt, or bioerode inside the urethra.

What is the protected technical concept?

The technical concept is localized delivery of a vasoactive prostaglandin through a small urethral insert rather than through an injection, oral tablet, topical cream, or conventional suppository.

The claim attempts to solve several delivery problems:

Avoiding intracavernosal injection.
Delivering a low mass of active pharmaceutical ingredient.
Retaining the active composition in a urethral shaft.
Promoting release through a dispersible carrier.
Allowing optional use of a permeation enhancer or additional vasodilator.

The patent therefore combines device structure, pharmaceutical composition, and route of administration in a single claim set.

How broad is independent claim 1?

Claim 1 has substantial breadth at the ingredient and carrier level but meaningful limits at the device level.

Elements that broaden claim 1

Claim 1 does not restrict:

The specific prostaglandin.
The identity of the dispersant.
The shaft material.
The shaft length or diameter.
The exact dose.
The release rate.
The presence of a permeation enhancer.
The presence of additional vasodilators.
The manufacturing method.
The shape of the applicator or insertion device.

The phrase “a vasoactive prostaglandin” includes prostaglandin E1, prostaglandin E2, natural prostaglandins, synthetic prostaglandins, and analogs, subject to claim construction and specification support.

Elements that limit claim 1

The claim requires:

A “shaft.”
A shaft sized to be received within the male urethra.
A composition retained within the shaft.
A dispersant.
An effective amount of a vasoactive prostaglandin.
Treatment of erectile dysfunction.

A formulation applied directly to the urethral opening without a shaft would present a weaker literal infringement case. A solid insert that contains alprostadil but does not use a material that dissolves, melts, or bioerodes may also fall outside the narrower dispersant definitions, although claim 1 itself does not expressly require the specific functional language later recited in claim 8.

What do dependent claims 2 through 18 add?

Claim	Added limitation	Commercial or legal significance
2	Composition weighs no more than about 50 mg	Narrows the product to a low-mass urethral dosage form
3	Impotence treatment; 10-1,000 micrograms alprostadil and 50-1,000 micrograms prazosin	Targets a specific combination product
4	Urethral permeation enhancer	Covers compositions designed to increase mucosal uptake
5	One or more additional vasodilators	Extends the claim to combination therapy
6	Prostaglandin E1	Directly encompasses alprostadil-type products
7	Prostaglandin E2	Covers a different prostaglandin class member
8	Dispersant dissolves, melts, or bioerodes in the urethra	Adds a functional release requirement
9	Specified vasodilator classes	Covers multiple pharmacologic classes
10	Vasodilator is an alpha blocker	Narrows claim 5 to alpha-adrenergic blockade
11	Dose ranges for prostaglandin plus papaverine, phentolamine, prazosin, doxazosin, or terazosin	Provides detailed combination-drug coverage
12	About 10-2,000 micrograms of vasoactive prostaglandin	Retains the claim 11 combination context while narrowing the prostaglandin dose
13	Specified dispersants, including polyethylene glycol and cyclodextrins	Covers common excipient categories
14	Polyethylene glycol	Relevant to water-soluble carrier systems
15	Cyclodextrin	Covers complexation and solubility-enhancement systems
16	Natural or synthetic prostaglandins, PGE1, alprostadil, misoprostol, enprostil, PGE2, and analogs	Defines a broad prostaglandin genus
17	Agent consists essentially of alprostadil and prazosin	Narrows the active combination while allowing excipients and non-active components
18	Composition less than about 100 mg	Adds a low-mass limitation, although the dependency is drafted as “claims 1” rather than “claim 1”

Claims 3, 11, and 17 carry the greatest product-specific relevance because they address alprostadil combined with alpha-blockers, especially prazosin. Claims 6, 13, and 14 are more relevant to an alprostadil-only product using polyethylene glycol or a similar carrier.

What formulations are protected by US 5,773,020?

The patent claims formulations based on a dispersible urethral carrier. Claim 13 identifies:

Polyethylene glycol.
Propylene glycol.
Glycerine.
Polyvinyl pyrrolidone.
Polyvinyl alcohol.
Hydroxyalkyl celluloses.
Cyclodextrins.

The claims do not require one particular dosage form geometry. The protected product could be a small rod, pellet, insert, or similar shaft-based form if it satisfies the structural and functional limitations.

What is the significance of polyethylene glycol?

Polyethylene glycol is expressly recited in claim 13 and separately in claim 14. A polyethylene-glycol carrier containing a vasoactive prostaglandin in a urethral shaft would fall within the literal scope of those claims if the remaining limitations were satisfied.

The presence of polyethylene glycol alone is not enough. The product must also use a shaft sized for male urethral insertion and contain an effective amount of the prostaglandin.

What is the significance of cyclodextrins?

Cyclodextrins are expressly included in claim 13 and independently recited in claim 15. Their inclusion indicates that the patent sought coverage for solubility-enhancing or complexation-based carrier systems, not only simple polyethylene-glycol matrices.

A later product using a cyclodextrin-prostaglandin complex could avoid claim 14 but would still face claim 15 if the shaft and urethral dosage-form limitations were met.

Does the patent cover MUSE and alprostadil urethral suppositories?

The claim set reads directly on the general product concept behind MUSE: an intraurethral alprostadil dosage form delivered through an applicator into the urethra. Claim 6 expressly identifies prostaglandin E1, and claim 16 expressly identifies alprostadil.

The patent is broader than MUSE in some respects. It covers:

PGE1 and PGE2.
Alprostadil and other analogs.
Single-agent and combination products.
Multiple dispersants.
Products with or without permeation enhancers.
Products using additional vasodilators.

It is narrower than every possible alprostadil product because it requires the claimed shaft-based urethral dosage form.

When did US Patent 5,773,020 lose exclusivity?

The patent has expired under the standard United States patent-term framework. The term for a utility patent generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory provisions.[1]

Public patent records place US 5,773,020 in the mid-1990s filing period, with a grant date of June 30, 1998. Its ordinary patent term therefore ended in the mid-2010s. No current enforceable patent term remains for the claims quoted by the user.

Expiration of this patent does not automatically terminate every patent right associated with MUSE or intraurethral alprostadil. Later continuation, divisional, formulation, applicator, manufacturing, or method-of-use patents must be reviewed separately.

What is the Orange Book status of US Patent 5,773,020?

MUSE was approved by the FDA as an alprostadil urethral suppository for erectile dysfunction. The relevant approved product is associated with NDA 020860 and was marketed by Vivus and later commercial partners.[2][3]

The Orange Book analysis must distinguish between:

The original patent.
Later patents listed against the MUSE NDA.
Regulatory exclusivity.
Patent term extension.
Patents that protected the product at the time of generic filing.

US 5,773,020 is no longer a current exclusivity barrier because its term has ended. Its historical Orange Book listing, if present during the relevant period, could have supported a Paragraph IV certification by an ANDA applicant while the patent remained listed and unexpired. It cannot now independently prevent approval or launch based on patent expiration.

The FDA’s Orange Book is the controlling source for current patent-listing status, expiration data, and exclusivity codes. Patent databases alone do not establish whether a patent was listed against a particular NDA.[2]

Were there Paragraph IV challenges to this patent?

A Paragraph IV certification would have been legally relevant only while the patent was listed and unexpired or while its claims could affect approval timing. Under the Hatch-Waxman Act, an ANDA applicant may certify that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed.[4]

The record for US 5,773,020 should be evaluated in the context of the complete MUSE patent portfolio. A Paragraph IV challenge could have targeted:

The shaft limitation.
The “retained within said shaft” limitation.
The definition of a dispersant.
The prostaglandin requirement.
The scope of claims directed to alprostadil and polyethylene glycol.
Obviousness based on earlier urethral delivery and prostaglandin disclosures.
Written-description or enablement issues for broad prostaglandin and vasodilator genera.

Because the patent has expired, a new ANDA applicant would not need to defeat the patent to obtain approval. A historic Paragraph IV notice would remain relevant to litigation history, settlement analysis, and launch chronology, but it would not create a present injunction risk under this patent.

What patent litigation affects this patent and the MUSE portfolio?

The relevant litigation risk is portfolio-based rather than limited to US 5,773,020. MUSE-related patent analysis should include:

Patent infringement suits involving an ANDA applicant.
Declaratory-judgment actions concerning listed patents.
Paragraph IV notice letters.
Settlements that set an agreed generic-entry date.
Later patents covering applicator geometry, manufacturing, formulation, or release characteristics.
Patent-term calculations for continuation patents.

No current litigation risk can be attributed to the expired claims of US 5,773,020 alone. A commercial entrant could still face litigation under later patents if those patents remain unexpired and are listed against the relevant FDA product.

How does US 5,773,020 compare with related MUSE patents?

The patent family should be separated into technical layers.

Patent layer	Typical subject matter	Relevance to a competing product
Delivery-device patents	Applicator, shaft, insertion geometry, and placement	High if the competitor uses a similar applicator
Core dosage-form patents	Prostaglandin-containing urethral shaft and dispersible carrier	Directly relevant to US 5,773,020
Formulation patents	Excipient selection, solubility, stability, release, and permeation	Relevant to formulation design
Method-of-use patents	Treatment of erectile dysfunction with intraurethral prostaglandin	Relevant to labeled use and inducement theories
Manufacturing patents	Molding, loading, drying, assembly, and packaging	Relevant to supply-chain and process design
Later continuation patents	Narrower improvements with later expiration dates	May create the principal residual risk

Earlier MUSE-related patents include US 5,242,391, while later patents include US 6,037,346 and US 6,727,256. Their exact scope and legal status must be assessed claim by claim rather than inferred from the existence of US 5,773,020.[5][6][7]

US 5,773,020 is best characterized as a core dosage-form patent. It is not necessarily the final or only patent controlling an applicator or a commercial manufacturing process.

How strong was the patent estate?

Claim-strength assessment

Issue	Assessment
Core concept	Strong commercial relevance because it covers the central urethral insert architecture
Claim breadth	Broad at the active-ingredient and excipient level
Structural limitations	Meaningful narrowing through the required urethral shaft
Design-around potential	Moderate; alternatives include non-shaft delivery, different release architecture, or a different route
Obviousness exposure	Material because urethral drug delivery, prostaglandins, and dispersible carriers were known technical areas
Written-description exposure	Greater for broad combinations and large classes of prostaglandins or vasodilators
Current enforceability	None because the patent has expired
Historical blocking value	High for products launched during the patent term
Residual portfolio risk	Dependent on later patents, not this patent alone

The strongest practical claims were likely those tied to the commercial product architecture: claims 1, 6, 13, and 14. Claims 3, 11, and 17 were narrower and more vulnerable to non-infringement if a competing product omitted prazosin or used a different vasodilator strategy.

What generic entry risks exist for intraurethral alprostadil?

The expired patent removes one principal barrier, but generic entry may still face non-patent obstacles:

Limited market size for urethral alprostadil.
Manufacturing complexity for a low-dose urethral insert.
Dose uniformity at microgram quantities.
Stability of alprostadil in the carrier.
Applicator design and human-factors requirements.
Demonstration of pharmaceutical equivalence.
FDA requirements for device-drug combination products.
Commercial competition from oral PDE5 inhibitors and intracavernosal products.
Potential later patents covering formulation, delivery, or manufacturing.

An applicant developing a competing product should avoid relying only on an alprostadil formulation analysis. The relevant freedom-to-operate review must include the applicator, shaft dimensions, excipient system, release profile, manufacturing steps, labeling, and all live patents listed against the reference product.

Is biosimilar risk relevant?

No. Alprostadil is a chemically synthesized small molecule, not a biologic. Biosimilar approval under the Public Health Service Act is not the relevant pathway.

A competing alprostadil product would generally be evaluated through an abbreviated new drug application or, depending on the product and formulation differences, a full or hybrid regulatory pathway. The principal legal issues are generic-drug equivalence, device comparability, patent certification, and product-specific exclusivity, not biosimilar interchangeability.[2][4]

What licensing and commercial issues matter?

MUSE commercialization involved the product sponsor, manufacturing partners, and commercial license arrangements over time. A license to commercialize MUSE or alprostadil does not establish ownership of every patent in the field. Commercial diligence should separate:

Patent ownership.
FDA NDA ownership.
Manufacturing rights.
Regional commercialization rights.
Rights to applicator technology.
Rights to formulation technology.
Rights to improvements and continuation patents.

The economic exposure of US 5,773,020 is now historical. Its commercial value during the protected period was tied to MUSE revenue and the absence of a therapeutically equivalent intraurethral competitor. Current revenue exposure depends on the surviving patent portfolio and the commercial viability of a generic entrant, not on the expired patent itself.

What geographic coverage does the patent provide?

US 5,773,020 provides rights only in the United States. It does not block products in Europe, Canada, Japan, or other markets.

International protection would require corresponding national or regional patents. A global launch review should map:

United States patents and Orange Book listings.
European Patent Office family members.
Canadian and Japanese counterparts.
Patent expiry by jurisdiction.
Local patent-term extensions.
National litigation and settlement records.

The expiration of the US patent does not establish expiration of every foreign counterpart.

Key Takeaways

US 5,773,020 covers a urethral shaft containing a dispersible composition with a vasoactive prostaglandin.
Claim 1 is broad across prostaglandins, dispersants, doses, and additional vasodilators, but it requires the shaft-based urethral dosage form.
Claims 6, 13, and 14 are particularly relevant to alprostadil products using polyethylene glycol or related dispersants.
Claims 3, 11, and 17 target alprostadil-plus-alpha-blocker combinations, especially prazosin.
The patent expired in the mid-2010s under the standard 20-year patent-term framework.
It no longer independently blocks generic approval or launch.
MUSE-related residual risk must be assessed through later formulation, applicator, manufacturing, and continuation patents.
Biosimilar analysis is not applicable because alprostadil is a small-molecule drug.
A current freedom-to-operate review must examine the full MUSE patent family, FDA Orange Book listings, device patents, and product-specific litigation history.

FAQs

Can a company launch an alprostadil urethral insert after US 5,773,020 expired?

Yes, expiration removes the patent’s exclusionary effect. The product must still satisfy FDA requirements and avoid infringement of any later unexpired patents.

Does using a different prostaglandin avoid the patent?

Not necessarily. The claims expressly encompass multiple prostaglandins, including PGE1, PGE2, alprostadil, misoprostol, enprostil, and analogs. A non-infringement position would need to address every claim limitation.

Does a polyethylene-glycol formulation infringe automatically?

No. Polyethylene glycol is only one claim limitation. The product must also include the required urethral shaft, retained composition, vasoactive prostaglandin, dispersant function, and other applicable limitations.

Can a non-urethral alprostadil product infringe US 5,773,020?

The quoted claims require a dosage form sized for receipt within the male urethra. Oral, injectable, topical, or ordinary transdermal products generally would not satisfy that limitation.

Does patent expiration eliminate all MUSE-related litigation risk?

No. Later patents may cover the applicator, formulation, manufacturing process, release characteristics, or other product improvements. The expired patent should be treated as one layer of the broader MUSE patent estate.

References

United States Patent and Trademark Office. (2024). Patent term adjustment and patent term information. https://www.uspto.gov/patents/apply/adjustments
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (2018). MUSE (alprostadil) urethral suppository prescribing information.
21 U.S.C. § 355(j). Abbreviated new drug applications and patent certifications.
U.S. Patent No. 5,242,391. (1993). Method and device for administering drugs to the urethra.
U.S. Patent No. 5,773,020. (1998). Urethral suppository.
U.S. Patent No. 6,037,346. (2000). Urethral suppository.
U.S. Patent No. 6,727,256. (2004). Urethral drug delivery system.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	173603	⤷ Start Trial
Australia	655420	⤷ Start Trial
Australia	7856391	⤷ Start Trial
Canada	2040914	⤷ Start Trial
Canada	2352552	⤷ Start Trial
Germany	69130529	⤷ Start Trial
Denmark	0526566	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,773,020

Summary for Patent: 5,773,020